[go: up one dir, main page]

FI20040675A0 - Metod för vård och förebyggandet av hjärthypertrofi - Google Patents

Metod för vård och förebyggandet av hjärthypertrofi

Info

Publication number
FI20040675A0
FI20040675A0 FI20040675A FI20040675A FI20040675A0 FI 20040675 A0 FI20040675 A0 FI 20040675A0 FI 20040675 A FI20040675 A FI 20040675A FI 20040675 A FI20040675 A FI 20040675A FI 20040675 A0 FI20040675 A0 FI 20040675A0
Authority
FI
Finland
Prior art keywords
treating
cardiac hypertrophy
preventing cardiac
preventing
hypertrophy
Prior art date
Application number
FI20040675A
Other languages
English (en)
Finnish (fi)
Inventor
Heimo Haikala
Petri Kaheinen
Jouko Levijoki
Piero Pollesello
Eero Mervaala
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Priority to FI20040675A priority Critical patent/FI20040675A0/sv
Publication of FI20040675A0 publication Critical patent/FI20040675A0/sv
Priority to PCT/FI2005/000219 priority patent/WO2005107756A1/en
Priority to EP05739484A priority patent/EP1744753A1/en
Priority to CA002564025A priority patent/CA2564025A1/en
Priority to US11/596,065 priority patent/US20080153827A1/en
Priority to JP2007512236A priority patent/JP2007537208A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI20040675A 2004-05-12 2004-05-12 Metod för vård och förebyggandet av hjärthypertrofi FI20040675A0 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI20040675A FI20040675A0 (sv) 2004-05-12 2004-05-12 Metod för vård och förebyggandet av hjärthypertrofi
PCT/FI2005/000219 WO2005107756A1 (en) 2004-05-12 2005-05-12 A method for the treatment or prevention of cardiac hypertrophy
EP05739484A EP1744753A1 (en) 2004-05-12 2005-05-12 A method for the treatment or prevention of cardiac hypertrophy
CA002564025A CA2564025A1 (en) 2004-05-12 2005-05-12 A method for the treatment or prevention of cardiac hypertrophy
US11/596,065 US20080153827A1 (en) 2004-05-12 2005-05-12 Method for the Treatment or Prevention of Cardiac Hypertrophy
JP2007512236A JP2007537208A (ja) 2004-05-12 2005-05-12 心臓肥大の治療または予防方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20040675A FI20040675A0 (sv) 2004-05-12 2004-05-12 Metod för vård och förebyggandet av hjärthypertrofi

Publications (1)

Publication Number Publication Date
FI20040675A0 true FI20040675A0 (sv) 2004-05-12

Family

ID=32338384

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20040675A FI20040675A0 (sv) 2004-05-12 2004-05-12 Metod för vård och förebyggandet av hjärthypertrofi

Country Status (6)

Country Link
US (1) US20080153827A1 (sv)
EP (1) EP1744753A1 (sv)
JP (1) JP2007537208A (sv)
CA (1) CA2564025A1 (sv)
FI (1) FI20040675A0 (sv)
WO (1) WO2005107756A1 (sv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
JP2008533109A (ja) * 2005-03-14 2008-08-21 オリオン コーポレーション 利尿を促進するための複合治療
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2008087248A1 (en) * 2007-01-17 2008-07-24 Orion Corporation Levosimendan for use in treating chronic valvular disease
US20100022552A1 (en) * 2007-06-15 2010-01-28 Kaohsiung Medical University Kmup-1 capable of treating hypertension
CA2744505A1 (en) * 2008-11-25 2010-06-03 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
CA2915445C (en) 2013-07-19 2024-04-23 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
EA201992230A1 (ru) 2013-12-04 2020-02-28 Бёрингер Ингельхайм Ветмедика Гмбх Улучшенные фармацевтические композиции пимобендана
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EP3993773A1 (en) 2019-07-01 2022-05-11 Orion Corporation Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide
WO2021126884A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
FI981473L (sv) * 1998-06-25 1999-12-26 Orion Yhtymae Oyj Förfarande för behandling av pulmonal hypertension
US6632628B1 (en) * 1999-08-20 2003-10-14 Board Of Regents, The University Of Texas System Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

Also Published As

Publication number Publication date
WO2005107756A1 (en) 2005-11-17
EP1744753A1 (en) 2007-01-24
CA2564025A1 (en) 2005-11-17
US20080153827A1 (en) 2008-06-26
JP2007537208A (ja) 2007-12-20

Similar Documents

Publication Publication Date Title
PL2520295T3 (pl) Sposób zapobiegania i leczenia zapalenia błon śluzowych
DK1929123T3 (da) Fremgangsmåde og anordning i tilknytning til stimulationsbehandlinger af borehuller
EP1906980A4 (en) METHOD OF TREATING OR MANAGING STRESS
NO20030265D0 (no) Fremgangsmåter ved behandling av borebrönner
FI20040675A0 (sv) Metod för vård och förebyggandet av hjärthypertrofi
NO20053565D0 (no) Nedihulls malesystem og fremgangsmate
FI20065359A0 (sv) Förfarande och armbandsanordning
FI20020822A7 (sv) Byggnadskiva och förfarande för fastsättning av en byggnadsskiva
DK1596868T3 (da) Fremgangsmåde til behandling af hjertesvigt og medikament dertil
ATE523594T1 (de) Modifizierung von pflanzenentwicklung und - morphologie
TWI366424B (en) Method of treating and probing a via
FI20020547A0 (sv) Metod och anordning för montering
FI20041288L (sv) Förbättrat alkaliskt massaframställningsförfarande och anläggning
DE602004031591D1 (de) Interferenzverminderung-Vorrichtung und -Verfahren
FI20031472A0 (sv) Förfarande vid nätriktare och nätriktare
EP1826223A4 (en) POLYETHER POLYOL, SYNTHESIS METHOD OF SAID COMPOUND AND APPLICATIONS
FI20021112A7 (sv) Förfarande och arrangemang för utförande av lokalisering
FI20031678A0 (sv) Förfarande för bearbetning av prov och arrangemang därför
FI116738B (sv) Ridåbeläggningsenhet och ridåbeläggningsförfarande
FI20045292L (sv) Förfarande i en frekvensomvandlare med spänningsmellankrets och frekvensomvandlare
FI20040831L (sv) Armbandsdator och förfarande i anslutning därtill
FI20041253L (sv) Reaktor och förfarande för fermentation på fast substrat
FI20030377A0 (sv) Förfarande vid kalandrering och kalander
FI20040360L (sv) Förfarande för trumbarkning av virke och motsvarande apparatur
FI20022061A0 (sv) Förfarande och arrangemang för att forma en konstruktion

Legal Events

Date Code Title Description
FD Application lapsed